Keywords: ciba, qlt, gain, priority, review, new, visudyne

CIBA and QLT gain priority review for new Visudyne use

Article | 31 August 2000

Print This

CIBA Vision and QLT Inc have received priority review status fromthe US Food and Drug Administration for Visudyne (verteporfin) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in